Recursion Pharmaceuticals witnessed a 27% decline in market value over the last week, a period marked by significant Executive and Board changes. The company appointed Dr. Namandjé Bumpus and ...

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...

Recursion Pharmaceuticals uses artificial intelligence (AI) in its proprietary operating system to match new compounds against a vast library of human genes in order to come up with new therapies.

Biotech stocks sold off hard last month. Negative company-specific and sector-specific news roiled these high-risk, high-upside plays. HHS Secretary Robert F. Kennedy Jr. appears to be a big ...

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC’s ...

Many of them have aimed to erase protections for transgender and non-binary Americans. One of the earliest was a Jan. 20 document, which recognized only two biological sexes: male and female.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals, Inc. before investing. In this article, we go over a ...